All News
#EULAR2023 #LB0003 It is unheard of therapies that potentially can improve Sjogren patients with high symptoms burden. Phase 2 RCT of Dazodalibep (CD40L-i) showed ESSPRI improved vs PBO. Numerical improvement in other secondary (Fatigue). Will await results in Phase 3 @RheumNow https://t.co/0NzR83apeY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies genuinely reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3
LB0003 #EULAR2023 @RheumNow https://t.co/HYcXEzswAg
David Liew drdavidliew ( View Tweet)
#Deeplearning in salivary biopsies in #SjogrensSyndrome - 327 pts - binary focus score (>=1) prediction the AUROC was 0.87 and for primary sjogrens diagnosis prediction it was 0.84
Quicker and cost effective in the future?
@rheumnow #EULAR2023 abst#OP0232 https://t.co/Ec0zuKqpXf
Bella Mehta bella_mehta ( View Tweet)
Could mitochondria play a role in the pathogenesis of Sjogrens disease?!
#Eular2023 https://t.co/XndW4qFf3E
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Malt lymphoma in Sjogrens disease and role of PET scan.
When is PET scan suggestive?
Follow:
Complement
RF
Focus score
SPEP
#Eular2023 https://t.co/60l8iRNvQN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#EULAR2023 #POS0120 From Sjogren to SLE. Interim analysis of Phase 2 RCT showed primary endpoint, SRI-4 + ability to sustain pred dose to ≤5 mg/d or ≤ BL from Wk16 to 28 was achieved more in Ianalumab (Bcell depletion & BAFF-R-i) vs PBO (44% vs 9%). Advance to Phase 3 @RheumNow https://t.co/Wg29uj5yqv
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #OP0142 From #Lupus to #Sjogren. A phase 2 RCT in China showed more patients on Telitacicept (BAFF/APRIL-i) achieved significant reduction in ESSDAI at Wk24 vs PBO. Trend to improvement in glandular function. Intriguing option & will await Phase 3 global RCT @RheumNow https://t.co/BCiohuAfP3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favoured DAZ Group. Phase 3 RCTs are underway @RheumNow https://t.co/I9uHxvRlnr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
Dr. Antoni Chan synovialjoints ( View Tweet)
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
David Liew drdavidliew ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/DMsjFzmjPn https://t.co/X1fg9ylo7g
Links:
Dr. John Cush RheumNow ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/SPmdBJ8IFh https://t.co/ad2j6XaSkK
Links:
Dr. John Cush RheumNow ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
d
MedPage Today
Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported, suggesting that BTK inhibitors might be useful in this population.
Read Article
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate uptoTate ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance.
https… https://t.co/r0AlTD45gG
Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Read Article
Potential new treatment for Sjogren's
Is there finally something new on the horizon in Sjogren’s syndrome?
Dr. Eric Dein. ( @ericdeinmd) discusses studies presented at #ACR22.
https://t.co/YinEPKlJb2 https://t.co/YOsc159GFt
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Abstr#2033 How negative is sero-ve #Sjogren? A study discovered new autoantibodies using Peptidome Array Technology. AUC for these 8 peptides was excellent 0.97. Mainly in White/Hispanic. Need validation in other groups and association with other markers/biopsy @RheumNow https://t.co/xAFrjK9mS3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9
Richard Conway RichardPAConway ( View Tweet)